Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F21%3A73610668" target="_blank" >RIV/61989592:15110/21:73610668 - isvavai.cz</a>

Result on the web

<a href="http://biomed.papers.upol.cz/artkey/bio-202101-0005_mouse-models-of-myeloproliferative-neoplasms-for-pre-clinical-testing-of-novel-therapeutic-agents.php" target="_blank" >http://biomed.papers.upol.cz/artkey/bio-202101-0005_mouse-models-of-myeloproliferative-neoplasms-for-pre-clinical-testing-of-novel-therapeutic-agents.php</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2021.004" target="_blank" >10.5507/bp.2021.004</a>

Result language

angličtina

Original language name

Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents

Original language description

Myeloproliferative neoplasms (MPN), are clonal hematopoietic stem cell (HSC) disorders driven by gain-of-function mutations in JAK2 (JAK2-V617F), CALR or MPL genes. MPN treatment options currently mainly consist of cytoreductive therapy with hydroxyurea and JAK2 inhibitors such as ruxolitinib and fedratinib. Pegylated interferon-alpha can induce complete molecular remission (CMR) in some MPN patients when applied at early stages of disease. The ultimate goal of modern MPN treatment is to develop novel therapies that specifically target mutant HSCs in MPN and consistently induce CMR. Basic research has identified a growing number of candidate drugs with promising effects in vitro. A first step on the way to developing these compounds into drugs approved for treatment of MPN patients often consists of examining the effects in vivo using pre-clinical mouse models of MPN. Here we review the current state of MPN mouse models and the experimental setup for their optimal use in drug testing. In addition to novel compounds, combinatorial therapeutic approaches are often considered for the treatment of MPN. Optimized and validated mouse models can provide an efficient way to rapidly assess and select the most promising combinations and thereby contribute to accelerating the development of novel therapies of MPN.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

<a href="/en/project/GA17-05988S" target="_blank" >GA17-05988S: Initiation and progression of myeloproliferative disorders – the role of pathological JAK2 activation in the specific context of EPOR</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

BIOMEDICAL PAPERS-OLOMOUC

ISSN

1213-8118

e-ISSN

—

Volume of the periodical

165

Issue of the periodical within the volume

1

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

8

Pages from-to

26-33

UT code for WoS article

000629606300005

EID of the result in the Scopus database

2-s2.0-85103169659